Lixisenatide

Lixisenatide is a once-daily, prandial GLP-1 receptor agonist derived from exendin-4, with a 44-amino-acid sequence that includes a C-terminal hexalysine tail. Approved in the US as Adlyxin (2016) and in the EU as Lyxumia (2013), it is notable for completing the first-ever GLP-1 RA cardiovascular outcomes trial (ELIXA, N=6,068), which demonstrated noninferiority for MACE but no superiority. Its prandial (pre-meal) dosing profile emphasizes postprandial glucose control. Immunogenicity is the highest in the GLP-1 RA class, with approximately 70% of patients developing anti-drug antibodies. Lixisenatide is not approved for weight management or CV risk reduction claims.

Lixisenatide is a GLP-1 receptor agonist based on the exendin-4 backbone. Like exenatide, it is naturally resistant to DPP-IV degradation due to the N-terminal His-Gly sequence. The C-terminal hexalysine tail was introduced to modulate pharmacokinetics, reducing interindividual variability. The half-life is approximately 3 hours, but receptor binding characteristics allow once-daily dosing when administered before the main meal of the day (typically breakfast). Lixisenatide has a pronounced effect on postprandial glucose via delayed gastric emptying and reduced glucagon secretion, with more modest effects on fasting glucose compared to basal insulin or longer-acting GLP-1 RAs. It is predominantly cleared by glomerular filtration and tubular catabolism (Rosenstock et al., Diabetes Care 2013).

Approved labeled regimen

The label summary below is product-, indication-, and jurisdiction-specific; consult the full current label and a licensed clinician/pharmacist.

The entry summarizes the cited US FDA Adlyxin label for type 2 diabetes.

• Initiate 10 mcg SC once daily within 1 hour before the same meal (preferably the main meal) for 14 days.

• Increase to maintenance dose of 20 mcg SC once daily from day 15.

• Administer SC in abdomen, thigh, or upper arm. If a dose is missed, skip it and resume with the next scheduled dose.

Studied regimens (not recommendations)

• ELIXA and GetGoal trials used the 20 mcg daily maintenance regimen.

• The 10 mcg initiation dose was added to reduce GI side effects during titration.

What is not established

• Once-weekly formulation (not developed; only daily dosing studied).

• Effectiveness in patients with HbA1c >10% or severe hyperglycemia.

• Use without concomitant metformin or basal insulin (most trials were add-on therapy).

• Weight management indication — no dedicated trial.

• CV risk reduction claim — ELIXA showed neutrality, not superiority.

Established label risks

• Gastrointestinal: Nausea (24–33%), vomiting (7–12%), diarrhea. Lower GI dropout rates than exenatide in head-to-head GetGoal-X.

• Acute pancreatitis: Postmarketing reports; discontinue if suspected.

• Acute kidney injury: Reports in setting of severe GI symptoms; use caution in renal impairment.

• Hypoglycemia: Low risk with monotherapy; higher with sulfonylurea or basal insulin coadministration (as in GetGoal-L).

• Immunogenicity: Highest in class — 70% anti-drug antibody positive in clinical trials; 2.7% high-titer antibodies with reduced efficacy (vs ~6% for Bydureon).

Human-study signals

• ELIXA: No signal for pancreatitis (1.2% vs 1.2%), pancreatic cancer, or thyroid malignancy.

• ELIXA: Higher serious GI events (6.0% vs 4.9%).

• ELIXA: No excess heart failure hospitalization (HR 0.96, 0.75–1.23).

• Injection-site reactions reported in ~1% of patients.

Unknowns and product-quality risks

• Clinical significance of high immunogenicity for long-term efficacy and safety is not fully characterized. Lower-titer antibodies do not affect efficacy; high-titer (~2.7%) attenuate HbA1c response.

• No data on cross-reactivity of anti-lixisenatide antibodies with native GLP-1 or exenatide.

• No long-term safety data beyond 2.1 years (ELIXA median follow-up).

• No approved generic or biosimilar as of 2026. Product is a synthetic peptide (NDA, not BLA), so generic pathway (ANDA) is possible in principle.

• Delays gastric emptying; oral medications requiring rapid absorption should be taken separately (label suggests at least 1 hour before or 4 hours after lixisenatide). Clinical significance for drugs with narrow therapeutic index.

• Sulfonylurea or basal insulin: Increased hypoglycemia risk; consider dose reduction.

• Renal impairment: Limited data in severe impairment (CrCl below 30 mL/min). Use caution; no dose adjustment for mild/moderate (CrCl 30–89).

• Hepatic impairment: No dose adjustment; limited data in severe impairment.

• Pregnancy: Class C per FDA labeling; animal studies show toxicity; avoid unless benefit outweighs risk.

• Adlyxin has no FDA boxed warning; its contraindication is serious hypersensitivity.

• Sanofi discontinued promotional activities for Adlyxin in the US post-launch; brand remains available but not actively marketed.

• The product was in-licensed from Zealand Pharma; AVE 0010 references the Sanofi development code; ZP 10 references the Zealand Pharma code.

• WADA: GLP-1 receptor agonists are not prohibited. Not listed on the WADA Prohibited List.

• CVOT superiority (ELIXA was neutral — the only GLP-1 RA CVOT to miss superiority)

• Dedicated weight management trial

• Head-to-head vs once-weekly GLP-1 RAs (only compared to exenatide BID)

• Long-term efficacy and safety beyond ~2 years

• Clinical significance of high immunogenicity — need for antibody monitoring unclear

• Pediatric T2D data — no studies conducted

• Data in patients with eGFR below 15 mL/min

• Databases and registries: PubMed, FDA Drugs@FDA, ClinicalTrials.gov, DailyMed, EMA EPAR

• Search terms: "lixisenatide", "Adlyxin", "Lyxumia", "ELIXA", "GetGoal", "AVE 0010", "ZP 10"

• Last searched: 2026-08-06

• Inclusion emphasis: CVOT publication, phase 3 registration trials, FDA label, immunogenicity analyses

1. Pfeffer MA et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome (ELIXA). N Engl J Med. 2015;373(23):2247-2257. PMID: 26378985. https://doi.org/10.1056/NEJMoa1509225

2. Rosenstock J et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin (GetGoal-X). Diabetes Care. 2013;36(9):2945-2951. PMID: 23698396. https://doi.org/10.2337/dc12-2709

3. Bolli GB et al. Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med. 2014;31(2):176-184. PMID: 24117597. https://doi.org/10.1111/dme.12328

4. Riddle MC et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin (GetGoal-L). Diabetes Care. 2013;36(9):2489-2496. PMID: 23628617. https://doi.org/10.2337/dc12-2454

5. FDA. Adlyxin (lixisenatide) injection label. NDA 208471. Drugs@FDA. Revised 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208471s012lbl.pdf

6. Drucker DJ. Mechanisms of action and therapeutic application of GLP-1 and GIP receptor agonists. Cell Metab. 2018;27(4):740-756. PMID: 29617641. https://doi.org/10.1016/j.cmet.2018.03.001

7. Christensen M et al. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs. 2009;12(8):503-517. PMID: 19629885.